Key Points
- Director Mika Derynck sold 158,795 Enliven shares for approximately $9.6 million under a pre-arranged Rule 10b5-1 plan, reducing direct ownership by 64.5% to 87,373 shares.
- Enliven reported a quarterly loss of $0.49 per share, missing analysts’ $0.39-loss estimate, while the stock traded near its 52-week high with a market capitalization of about $3.67 billion.
- The company continues to receive positive investor signals, including encouraging clinical data, an expected cash runway into 2030, and a consensus “Moderate Buy” rating with a $72.67 price target.
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Mika Derynck sold 158,795 shares of the firm's stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total value of $9,561,046.95. Following the completion of the transaction, the director owned 87,373 shares in the company, valued at approximately $5,260,728.33. This trade represents a 64.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Enliven Therapeutics Price Performance
NASDAQ ELVN opened at $60.27 on Friday. Enliven Therapeutics, Inc. has a 1-year low of $14.78 and a 1-year high of $62.32. The firm has a market capitalization of $3.67 billion, a P/E ratio of -36.09 and a beta of 0.27. The business's 50-day simple moving average is $48.21 and its 200-day simple moving average is $39.53.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). On average, equities research analysts expect that Enliven Therapeutics, Inc. will post -1.57 EPS for the current fiscal year.
Hedge Funds Weigh In On Enliven Therapeutics
A number of hedge funds have recently bought and sold shares of ELVN. KBC Group NV acquired a new stake in Enliven Therapeutics during the first quarter valued at approximately $38,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Enliven Therapeutics by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company's stock worth $44,000 after buying an additional 594 shares during the last quarter. BNP Paribas Financial Markets grew its position in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock worth $75,000 after acquiring an additional 930 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of Enliven Therapeutics in the 4th quarter worth approximately $83,000. Finally, Quantbot Technologies LP increased its holdings in shares of Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company's stock valued at $90,000 after acquiring an additional 1,434 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.
Key Headlines Impacting Enliven Therapeutics
Here are the key news stories impacting Enliven Therapeutics this week:
- Positive Sentiment: Encouraging clinical progress: Enliven reported positive Phase 1 data for ELVN-001 in chronic myeloid leukemia, including encouraging efficacy and a favorable safety and tolerability profile. The company also said it reached agreement with the FDA on key components of the drug’s Phase 3 trial design. Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
- Positive Sentiment: Strong financial runway: Enliven ended the quarter with $895 million in cash, cash equivalents and marketable securities, which management expects to fund operations into 2030. This reduces near-term financing and dilution concerns for investors.
- Positive Sentiment: Analyst target increases: Goldman Sachs raised its price target from $67 to $80 and maintained a “buy” rating. Stifel Nicolaus also raised its target, from $80 to $82, while maintaining a “buy” rating. The revisions imply substantial upside from the stock’s recent trading level. Goldman Sachs price target update Stifel Nicolaus price target update
- Neutral Sentiment: Director sale: Director Mika K. Derynck sold 158,795 shares for approximately $9.6 million, reducing direct ownership by 64.5%. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, which may lessen concerns that the sale reflected a negative view of the company, although the transaction could still weigh on sentiment. SEC insider transaction filing
- Negative Sentiment: Quarterly loss exceeded expectations: Enliven reported a second-quarter loss of $0.49 per share, wider than the $0.39 loss analysts expected. The earnings miss contributed to an earlier pullback in the stock and highlights the company’s continuing lack of profitability. Enliven quarterly earnings release
Wall Street Analysts Forecast Growth
ELVN has been the topic of several research reports. HC Wainwright raised their price objective on Enliven Therapeutics from $56.00 to $64.00 and gave the company a "buy" rating in a research report on Thursday, July 9th. Mizuho increased their target price on Enliven Therapeutics from $45.00 to $62.00 and gave the company an "outperform" rating in a research note on Tuesday, June 2nd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Enliven Therapeutics in a report on Friday, July 17th. Wall Street Zen raised Enliven Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday, May 11th. Finally, Stifel Nicolaus upped their price target on Enliven Therapeutics from $80.00 to $82.00 and gave the stock a "buy" rating in a report on Thursday. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $72.67.
Check Out Our Latest Stock Analysis on Enliven Therapeutics
Enliven Therapeutics Company Profile
(
Get Free Report)
Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.
The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
